A randomized comparison of daunorubicin 90 mg/m2 vs 60 mg/m2 in AML induction: results from the UK NCRI AML17 trial in 1206 patients

K. Burnett, Alan; H. Russell, Nigel; K. Hills, Robert; Kell, Jonathan; Cavenagh, Jamie; Kjeldsen, Lars; McMullin, Mary‐Frances; Cahalin, Paul; Dennis, Mike; Smidstrup Friis, Lone; F. Thomas, Ian; Milligan, Don; E. Clark, Richard

doi:10.1182/blood-2015-01-623447

Public

A randomized comparison of daunorubicin 90 mg/m2 vs 60 mg/m2 in AML induction: results from the UK NCRI AML17 trial in 1206 patients

Published in Blood • Apr 2, 2015

Authors:

Alan K. Burnett

Nigel H. Russell

Robert K. Hills

Abstract

Modifying induction therapy in acute myeloid leukemia (AML) may improve the remission rate and reduce the risk of relapse, thereby improving survival. Escalation of the daunorubicin dose to 90 mg/m(2) has shown benefit for some patient subgroups when compared with a dose of 45 mg/m(2), and has been ...

Subject

Daunorubicin

Medicine

Internal medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!